keyword
https://read.qxmd.com/read/31870225/remote-digital-monitoring-of-medication-intake-methodological-medical-ethical-and-legal-reflections
#21
JOURNAL ARTICLE
Wim Van Biesen, Johan Decruyenaere, Katerina Sideri, Julian Cockbain, Sigrid Sterckx
In 2017, regulatory approval was given in the US for a 'digital pill', a pill for which actual ingestion could be remotely monitored. The pill, Abilify Mycite is marketed by Otsuka but the monitoring system derives from Proteus Digital Health. In this paper, we focus on this digital pill and another equivalent system from AiCure which relies on facial recognition. Both systems not only remind the patient to take a pill but also verify the actual intake. In this process, patient-related data beyond the fact that the pill has been taken are also collected and sent to a remote computer system of the system-providing company and possibly to third parties...
December 23, 2019: Acta Clinica Belgica
https://read.qxmd.com/read/31354275/symptomatic-stability-with-aripiprazole-once-monthly-efficacy-analyses-from-acute-and-long-term-studies
#22
JOURNAL ARTICLE
Jessica J Madera, Pedro Such, Cathy Zhao, Ross A Baker
Objective: To evaluate the effect of aripiprazole once-monthly 400 mg (AOM 400; Abilify Maintena® ) on symptom stability in acute treatment and maintenance therapy settings in patients with schizophrenia. Methods: Results were analyzed from two pivotal maintenance studies (Studies 246 and 247), a long-term (52 weeks), open-label extension of these studies (Study 248), an open-label, mirror-image study in patients switching from oral to long-acting injectable antipsychotic therapy (Study 283), and a study of AOM 400 in the acute setting (Study 291)...
2019: Neuropsychiatric Disease and Treatment
https://read.qxmd.com/read/31320322/digital-aripiprazole-or-digital-evergreening-a-systematic-review-of-the-evidence-and-its-dissemination-in-the-scientific-literature-and-in-the-media
#23
JOURNAL ARTICLE
Lisa Cosgrove, Ioana Alina Cristea, Allen F Shaughnessy, Barbara Mintzes, Florian Naudet
BACKGROUND: In November 2017, the Food and Drug Administration (FDA) approved a version of a second-generation antipsychotic, aripiprazole, embedded with a sensor (Abilify MyCite). OBJECTIVE: To systematically review the evidence supporting the FDA's approval of digital aripiprazole and how that evidence was disseminated in the scientific literature and news reports. STUDY SELECTION: Prospective, double-blind, randomised controlled trials (RCTs), non-randomised and non-comparative studies were included if they focused on the use of digital aripiprazole...
December 2019: BMJ Evidence-Based Medicine
https://read.qxmd.com/read/31296992/the-effect-of-aripiprazole-once-monthly-on-personal-and-social-functioning-post-hoc-analyses-of-acute-and-long-term-studies
#24
JOURNAL ARTICLE
Timothy Peters-Strickland, Ross A Baker, Pedro Such, Peter Zhang, Jessica J Madera
OBJECTIVE: To evaluate the effect of aripiprazole once-monthly 400 mg (AOM 400; Abilify Maintena® ) on personal and social functioning in patients with schizophrenia in both the acute treatment and maintenance therapy settings. METHODS: Post hoc analyses were conducted on data from Study 291 (NCT01663532), a 12-week, randomized, double-blind, placebo-controlled trial conducted in patients who were experiencing an acute psychotic episode, and Study 248 (NCT00731549), a 52-week open-label extension of two randomized, controlled trials of AOM 400 as maintenance therapy...
2019: Neuropsychiatric Disease and Treatment
https://read.qxmd.com/read/30991969/real-life-assessment-of-aripiprazole-monthly-abilify-maintena-in-schizophrenia-a-canadian-naturalistic-non-interventional-prospective-cohort-study
#25
MULTICENTER STUDY
Sally Mustafa, Joanna Bougie, Maia Miguelez, Guerline Clerzius, Emmanouil Rampakakis, Jean Proulx, Ashok Malla
BACKGROUND: With previously established efficacy of aripiprazole once-monthly injectable formulation (AOM) in pre-registration randomized controlled trials, the current study was designed to evaluate its effectiveness in patients treated for schizophrenia in regular clinical settings in Canada. METHODS: Following their clinicians' decision to prescribe AOM, 193 patients with a diagnosis of schizophrenia, were recruited from 17 Canadian community or hospital-based settings...
April 16, 2019: BMC Psychiatry
https://read.qxmd.com/read/30856161/aripiprazole-with-digital-ingestion-tracking-abilify-mycite
#26
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
January 28, 2019: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/30292748/process-control-and-in-vitro-in-vivo-evaluation-of-aripiprazole-sustained-release-microcrystals-for-intramuscular-injection
#27
JOURNAL ARTICLE
Qing Cai, Luying He, Silin Wang, Wei Chu, Lingli Zhou, Wenli Pan, Lu Zhang, Shan Jiang, Dangyang Ma, Xue Liang, Jingxin Gou, Tian Yin, Yu Zhang, Xing Tang, Haibing He
This work describes the preparation of aripiprazole sustained-release microcrystals for intramuscular injection, through recrystallization, drying, wet grinding, and solidification steps, which had a great impact on the product quality. Here, we evaluated the crystal form of the drug in each step by differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD), and fourier transform infrared spectroscopy (FT-IR), demonstrating that there is no change in the crystal form of aripiprazole monohydrate (H1) during grinding and freeze-drying...
December 1, 2018: European Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/30275787/hyponatremia-in-association-with-second-generation-antipsychotics-a-systematic-review-of-case-reports
#28
REVIEW
Sarah Naz Ali, Lydia A Bazzano
Background: Hyponatremia is generally defined as a serum sodium level <135 mmol/L and is considered severe if serum sodium is <125 mmol/L. Hyponatremia is a potentially life-threatening medical comorbidity for patients with schizophrenia. The incidence of hyponatremia in patients with schizophrenia who are taking second-generation antipsychotics (SGAs) has not been well established. Methods: We conducted a systematic review of case reports of hyponatremia associated with the use of SGAs in patients with schizophrenia...
2018: Ochsner Journal
https://read.qxmd.com/read/29341820/comments-on-abilify-mycite
#29
JOURNAL ARTICLE
John M Kane
No abstract text is available yet for this article.
January 2018: Clinical Schizophrenia & related Psychoses
https://read.qxmd.com/read/29189543/acute-angle-closure-glaucoma-associated-with-aripiprazole-in-the-setting-of-plateau-iris-configuration
#30
JOURNAL ARTICLE
Elizabeth Shen, Sarah Farukhi, Mason Schmutz, Sameh Mosaed
PURPOSE OF THE STUDY: The purpose of this study was to report a novel case of drug-induced angle-closure from aripiprazole (Abilify), an atypical antipsychotic, and propose a mechanism for this association. METHODS/RESULTS: We report a case of a 45-year-old white woman who presented in subacute angle closure 2 months after initiating aripiprazole 5 mg daily for depression. This patient reported no prior ocular history and had been on longstanding duloxetine (Cymbalta) 60 mg daily for over 10 years before starting aripiprazole...
February 2018: Journal of Glaucoma
https://read.qxmd.com/read/28595931/aripiprazole-induced-adverse-metabolic-alterations-in-polyi-c-neurodevelopmental-model-of-schizophrenia-in-rats
#31
JOURNAL ARTICLE
Katerina Horska, Jana Ruda-Kucerova, Eva Drazanova, Michal Karpisek, Regina Demlova, Tomas Kasparek, Hana Kotolova
Schizophrenia appears to be linked to higher incidence of metabolic syndrome even in the absence of antipsychotic treatment. Atypical antipsychotics substantially differ in their propensity to induce metabolic alterations. Aripiprazole is considered to represent an antipsychotic drug with low risk of metabolic syndrome development. The aim of this study was to evaluate metabolic phenotype of neurodevelopmental polyI:C rat model and assess metabolic effects of chronic aripiprazole treatment with regard to complex neuroendocrine regulations of energy homeostasis...
September 1, 2017: Neuropharmacology
https://read.qxmd.com/read/28579725/cost-savings-from-an-antipsychotic-tablet-splitting-program
#32
JOURNAL ARTICLE
Heather Carey, Mark Fondriest
BACKGROUND: Newer atypical antipsychotics such as aripiprazole (Abilify, Otsuka) and lurasidone (Latuda, Sunovion) have favorable safety and efficacy profiles, but their use is limited by high cost. University Hospitals Richmond Medical Center initiated an antipsychotic tablet-splitting program in August 2015 to counter the costs based on the identical pricing structure of aripiprazole and lurasidone doses. METHODS: A retrospective chart review was completed for all patients dispensed aripiprazole or lurasidone oral tablets from May 1, 2015, through December 31, 2015, to evaluate the potential cost-savings for our facility...
June 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://read.qxmd.com/read/28536511/aripiprazole-facilitates-extinction-of-conditioned-fear-in-adolescent-rats
#33
JOURNAL ARTICLE
Despina E Ganella, Liubov Lee-Kardashyan, Sophia J Luikinga, Danny L D Nguyen, Heather B Madsen, Isabel C Zbukvic, Russell Coulthard, Andrew J Lawrence, Jee Hyun Kim
Anxiety disorders are the most common type of mental disorder during adolescence, which is at least partly due to the resistance to extinction exhibited at this age. The dopaminergic system is known to be dysregulated during adolescence; therefore, we aimed to facilitate extinction in adolescent rats using the dopamine receptor 2 partial agonist aripiprazole (Abilify™), and examine the behavioral and neural outcomes. Adolescent rats were conditioned to fear a tone. The next day, rats received extinction 30 min after a systemic injection of either 5 mg/kg aripiprazole or vehicle, and then were tested the following day...
2017: Frontiers in Behavioral Neuroscience
https://read.qxmd.com/read/27708677/pharmacoeconomic-comparison-of-aripiprazole-once-monthly-and-paliperidone-palmitate-from-a-head-to-head-clinical-trial-in-schizophrenia-a-us-analysis
#34
JOURNAL ARTICLE
Christophe Sapin, Ann Hartry, Siddhesh A Kamat, Maud Beillat, Ross A Baker, Anna Eramo
Schizophrenia presents a substantial clinical and economic burden to the health-care system. In QUAlity of LIfe with AbiliFY Maintena (QUALIFY), a randomized head-to-head study of aripiprazole once-monthly 400 mg (AOM 400) compared with paliperidone palmitate (PP; 78-234 mg/mo), AOM 400 demonstrated greater improvement in health-related quality of life and functioning in patients with stable schizophrenia. The present analysis used health economics assessment data collected during the QUALIFY study to determine the direct medical and pharmacy costs and the cost-effectiveness associated with each treatment over 6 months...
2016: Drugs in Context
https://read.qxmd.com/read/26946126/role-of-dopamine-2-receptor-in-impaired-drug-cue-extinction-in-adolescent-rats
#35
JOURNAL ARTICLE
Isabel C Zbukvic, Despina E Ganella, Christina J Perry, Heather B Madsen, Christopher R Bye, Andrew J Lawrence, Jee Hyun Kim
Adolescent drug users display resistance to treatment such as cue exposure therapy (CET), as well as increased liability to relapse. The basis of CET is extinction learning, which involves dopamine signaling in the medial prefrontal cortex (mPFC). This system undergoes dramatic alterations during adolescence. Therefore, we investigated extinction of a cocaine-associated cue in adolescent and adult rats. While cocaine self-administration and lever-alone extinction were not different between the two ages, we observed that cue extinction reduced cue-induced reinstatement in adult but not adolescent rats...
2016: Cerebral Cortex
https://read.qxmd.com/read/26786936/clinical-effectiveness-and-patient-perspectives-of-different-treatment-strategies-for-tics-in-children-and-adolescents-with-tourette-syndrome-a-systematic-review-and-qualitative-analysis
#36
REVIEW
Chris Hollis, Mary Pennant, José Cuenca, Cris Glazebrook, Tim Kendall, Craig Whittington, Sarah Stockton, Linnéa Larsson, Penny Bunton, Suzanne Dobson, Madeleine Groom, Tammy Hedderly, Isobel Heyman, Georgina M Jackson, Stephen Jackson, Tara Murphy, Hugh Rickards, Mary Robertson, Jeremy Stern
BACKGROUND: Tourette syndrome (TS) is a neurodevelopmental condition characterised by chronic motor and vocal tics affecting up to 1% of school-age children and young people and is associated with significant distress and psychosocial impairment. OBJECTIVE: To conduct a systematic review of the benefits and risks of pharmacological, behavioural and physical interventions for tics in children and young people with TS (part 1) and to explore the experience of treatment and services from the perspective of young people with TS and their parents (part 2)...
January 2016: Health Technology Assessment: HTA
https://read.qxmd.com/read/26766033/availability-of-prescription-drugs-for-bipolar-disorder-at-online-pharmacies
#37
JOURNAL ARTICLE
Scott Monteith, Tasha Glenn, Rita Bauer, Jörn Conell, Michael Bauer
BACKGROUND: There is increasing use of online pharmacies to purchase prescription drugs. While some online pharmacies are legitimate and safe, there are many unsafe and illegal so-called "rogue" online pharmacies. This study investigated the availability of psychotropic drugs online to consumers in the US, using 5 commonly prescribed drugs for bipolar disorder. METHODS: Using the search term "buy [drug name]" in the Google, Yahoo and Bing search engines, the characteristics of the online pharmacies found on the first two pages of search results were investigated...
March 15, 2016: Journal of Affective Disorders
https://read.qxmd.com/read/26642668/clinical-experience-of-long-term-treatment-with-aripiprazole-abilify-in-children-and-adolescents-at-the-child-and-adolescent-psychiatric-clinic-1-in-roskilde-denmark
#38
JOURNAL ARTICLE
Beata Diomšina, Pernille Darling Rasmussen, Vita Danilevičiütė
The aim of this paper is to share the clinical experience of the treatment of aripiprazole (Abilify) in children and adolescents. The authors have done a cross-sectional study about Abilify's treatment in children and adolescents with severe conduct problems (high impulsivity, aggression, outward reaction, physical cross-border behavior), high restlessness with ADHD, psychotic and psychosis-like symptoms with autistic disorders, psychosis, and intensive tics with Tourette's syndrome. The authors studied and described patients at the Child and Adolescent Psychiatric Clinic 1 in Roskilde, Denmark, who were treated with Abilify and were patients of the clinic in June 2013...
May 2015: Acta Poloniae Pharmaceutica
https://read.qxmd.com/read/26289486/the-safety-efficacy-and-tolerability-of-abilify-maintena-for-the-treatment-of-schizophrenia
#39
JOURNAL ARTICLE
Rene S Kahn, Amalia Giannopoulou
Relapse in schizophrenia has been associated with poor adherence to oral medication. A possible method to optimize medication adherence could be to switch patients from oral to depot medication. In this respect, aripiprazole long acting injectable (ALAI) significantly delayed time to impending relapse when compared with placebo (p < 0.0001), while ALAI was generally well tolerated during both short-term and long-term studies. A literature search, using PubMed was conducted to identify relevant publications...
2015: Expert Review of Neurotherapeutics
https://read.qxmd.com/read/26235040/the-safety-efficacy-and-tolerability-of-abilify-maintena-for-the-treatment-of-schizophrenia
#40
Rene S Kahn, Amalia Giannopoulou
Relapse in schizophrenia has been associated with poor adherence to oral medication. A possible method to optimize medication adherence could be to switch patients from oral to depot medication. In this respect, aripiprazole long acting injectable (ALAI) significantly delayed time to impending relapse when compared with placebo (p < 0.0001), while ALAI was generally well tolerated during both short-term and long-term studies. A literature search, using PubMed was conducted to identify relevant publications...
August 2, 2015: Expert Review of Neurotherapeutics
keyword
keyword
40862
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.